178 related articles for article (PubMed ID: 18308914)
1. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.
Zhu B; Ascher-Svanum H; Shi L; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2008 Mar; 59(3):315-7. PubMed ID: 18308914
[TBL] [Abstract][Full Text] [Related]
2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.
Shi L; Ascher-Svanum H; Zhu B; Faries D; Montgomery W; Marder SR
Psychiatr Serv; 2007 Apr; 58(4):482-8. PubMed ID: 17412849
[TBL] [Abstract][Full Text] [Related]
4. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
5. Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.
Brnabic AJ; Kelin K; Ascher-Svanum H; Montgomery W; Kadziola Z; Karagianis J
Int J Clin Pract; 2011 Sep; 65(9):945-53. PubMed ID: 21849009
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.
Bitter I; Katona L; Zámbori J; Takács P; Fehér L; Diels J; Bacskai M; Lang Z; Gyáni G; Czobor P
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1383-90. PubMed ID: 23477752
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
[TBL] [Abstract][Full Text] [Related]
8. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
[TBL] [Abstract][Full Text] [Related]
9. Rehospitalization risk with second-generation and depot antipsychotics.
Conley RR; Kelly DL; Love RC; McMahon RP
Ann Clin Psychiatry; 2003 Mar; 15(1):23-31. PubMed ID: 12839430
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients.
Ascher-Svanum H; Peng X; Faries D; Montgomery W; Haddad PM
BMC Psychiatry; 2009 Jul; 9():46. PubMed ID: 19640279
[TBL] [Abstract][Full Text] [Related]
11. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.
Novick D; Haro JM; Bertsch J; Anand H; Jemiai N; Haddad PM
Int Clin Psychopharmacol; 2012 Sep; 27(5):275-82. PubMed ID: 22699789
[TBL] [Abstract][Full Text] [Related]
13. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Covell NH; McEvoy JP; Schooler NR; Stroup TS; Jackson CT; Rojas IA; Essock SM;
J Clin Psychiatry; 2012 May; 73(5):669-75. PubMed ID: 22480442
[TBL] [Abstract][Full Text] [Related]
15. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.
Olfson M; Marcus SC; Ascher-Svanum H
Schizophr Bull; 2007 Nov; 33(6):1379-87. PubMed ID: 17470444
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of inpatient depot antipsychotic prescribing.
Pabis DJ; Dorson PG; Crismon ML
Ann Pharmacother; 1996 Dec; 30(12):1381-6. PubMed ID: 8968447
[TBL] [Abstract][Full Text] [Related]
17. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
18. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Moore DB; Kelly DL; Sherr JD; Love RC; Conley RR
Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S17-9. PubMed ID: 9872689
[No Abstract] [Full Text] [Related]
19. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
Stanković Z; Ille T
Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia].
Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
